Vesicare (solifenacin) Trials

43 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Vesicare (solifenacin) / Astellas

ACTRN12611000796987: Effect of solifenacin and oxybutynin patch on cognitive function in elderly women with overactive bladder: An open-labelled, randomised, cross-over pilot study

Not yet recruiting

Bianca Wong, Department of Geriatric and Rehabilitation Medicine, Department of Obstetrics and Gynaecology, Memory Trials Centre

cognitive function, overactive bladder syndrome

ACTRN12610001022055: Solifenacin to relieve ureteral stent-related symptoms: A randomized, double-blinded placebo-controlled study

Recruiting

100

Mennonite Christian Hospital, Taiwan, Mennonite Christian Hospital, Taiwan

Ureteral stent-related symptoms after ureteroscopic stone manipulation.

ChiCTR-TNC-10000948: The Application of Overactive Bladder Symptom Score (OABSS) in Response to Treatment in Chinese Population

Completed

250

Vesicare 5mg-10mg/day Solifenacine

Beijing Hospital; Astellas Pharmaceuticals (China) Co., , Astellas Pharmaceuticals (China) Co.,

Overactive bladder

2006-001210-33: A cohort study of anticholinergic drugs in South Asian women with detrusor overactivity

Ongoing

Europe

Detrusitol XL, Vesicare, Detrusitol XL, Vesicare

University Hospitals of Leicester NHS Trust

The medical condidtion is overactive bladder .A wide range of different anticholinergic agents is available to treat overactive bladder (OAB) symptoms.Within the last 15 years, ethno-pharmacologic research has uncovered significant differences in how people in diverse ethnic groups metabolize certain drugs.

ChiCTR-IPR-17011523: Effectiveness of solifenacin for managing of bladder spasms in patients with urethroplasty

Recruiting

315

solifenacin ;vitamin C

Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Self-Funding

bladder spasm

2019-003321-14: 12-weeks, Open-label, Randomized, Multicenter, Post Marketing Clinical Follow-up Study to Evaluate Safety, Tolerability and Efficacy of the Home-Based electrical Transcutaneous NeuroModulation (eTNM) treatment via Nerve Stimulator URIS I (Tesla Medical) vs. Solifenacin in Treatment Nave Subjects With Overactive Bladder (OAB) 12týdenní randomizované, multicentrické post-marketingové klinické sledování bezpečnosti, snášenlivosti a účinnosti domácí léčby transkutánní elektrickou neuromodulací (eTNM) neuromodulačním zařízením URIS I (Tesla Medical) ve srovnání s přípravkem solifenacin v léčbě dosud neléčených subjektů se syndromem hyperaktivního močového měchýře (OAB)

Not yet recruiting

RoW

solsolifenacin-sukcinát (solifenacini succinas), Tablet, Vesicare 5mg

Tesla Medical s.r.o., Tesla Medical s.r.o

Naive Subjects With Overactive Bladder (OAB), Female Subjects with hyperactive overactive bladder, Diseases [C] - Nervous System Diseases [C10]

ChiCTR1900028650: Evaluation of the Efficacy of Mirabilon and Solifenacin for Preventing Catheter-Related Bladder Discomfort After Transurethral Resection Surgery: a Prospective, Randomized, Placebo-Controlled Study

Recruiting

Mirabegron 50mg ;Solifenacine ;Nil

Capital Medical University, Beijing Chaoyang Hospital; Capital Medical University, Beijing Chaoyang Hospital, Beijing Health system Special funds for High-level talents

Catheter Related Bladder Discomfort

NCT06197295: Efficacy of Combined Pharmacotherapy Versus Solifenacin with Vaginal Estrogen Cream for Women with Detrusor Overactivity

Recruiting

100

RoW

Solifenacin with vaginal estrogen cream, Premarin, Combination pharmacotherapy, Vesicare and Betmiga

Mackay Memorial Hospital

Urinary Bladder, Overactive, Effect of Drug

06/25

12/25

NCT06479720: Efficacy of Solifenacin or Mirabegron with Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

Recruiting

300

RoW

Combined pharmacotherapy with Solifenacin and Mirabegron, Vesicare and Betmiga, Solifenacin with vaginal estrogen cream, Vesicare and Premarin, Mirabegron with vaginal estrogen cream, Betmiga and Premarin

Mackay Memorial Hospital

Effect of Drug, Urinary Bladder, Overactive

12/24

06/25

NCT05494567: Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

Active, not recruiting

RoW

Tadalafil 5mg, rectalis 5 mg, Tamsulosin Hcl 0.4 mg, tamsulosin 0.4 mg, solifenacin 10 mg

Mansoura University

Benign Prostatic Hyperplasia, Overactive Bladder

08/22

NCT04909255: Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Recruiting

RoW

mirabegron, Betmiga, oxybutynin, tolterodine, solifenacin, Ditropan, tartrate, vesicare

China Medical University Hospital

Sjogren's Syndrome, Overactive Bladder Syndrome

08/22

SEPTOX, NCT04819360: Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

Terminated

Europe

VESIcare 10Mg Tablet, Vesicare, Botox 100 UNT Injection, Botox

Brigitte Schürch, Centre Hospitalier Universitaire Vaudois

Urinary Bladder, Neurogenic, Multiple Sclerosis

03/22

04/24

NCT06465576: Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

Recruiting

216

Europe

Solifenacin, Mirabegron, Solifenacin + Mirabegron

University of Aarhus

Urinary Incontinence in Children

12/27

NCT05968885: Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients with Detrusor Overactivity

Recruiting

300

RoW

Intradetrusor Botox® (onabotulinumtoxinA) injection, Combine Mirabegron and Solifenacin.

Mackay Memorial Hospital

Urinary Bladder, Overactive, Urodynamics, Effect of Drug

12/24

06/25

NCT04325880: Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Recruiting

240

RoW

Mirabegron 50 MG, Tamsulosin, Solifenacin Succinate 10 MG, Placebo oral tablet

Mansoura University

Ureteral Stent, Stent Related Symptoms

06/22

07/22

NCT05490082: Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Recruiting

100

RoW

Mirabegron, Propevirine, Solifenacin

Mansoura University

Voiding Disorders

03/23

10/23

BOSS PD, NCT03149809: Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

Completed

solifenacin, Vesicare, Pelvic floor muscle exercise-based behavioral therapy

VA Office of Research and Development

Overactive Bladder, Parkinson Disease

09/23

NCT05282069: A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Completed

607

RoW

DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg, Solifenacin 5mg, Solifenacin succinate placebo

Dong-A ST Co., Ltd.

Overactive Bladder

11/23

05/24

NCT06551246: Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children with Daytime Urinary Incontinence (BeDry)

Recruiting

236

Europe

Solifenacin, Mirabegron

University of Aarhus

Urinary Incontinence in Children

12/27

NCT04023253: Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

Recruiting

120

RoW

Mirabegron, Solifenacin

Far Eastern Memorial Hospital

Overactive Bladder Syndrome

12/24

NCT06803030: Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

Not yet recruiting

189

RoW

Tamsulosin Hydrochloride 0.4 mg, Cap. Urimax 0.4 mg, Solifenacin Succinate 5 mg, Tab. Solay 5 mg, Mirabegron 25 mg, Tab. Mirasin 25 mg

Bir Hospital, Nepal Health Research Council

Ureteral Stent-Related Symptom

06/25

12/26

NCT01530373: Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Recruiting

110

solifenacin, Vesicare, Clonidine, Catapres, Dixarit

University of Arkansas

Hot Flashes, Breast Cancer

07/26

09/27

MS.21.09.1680, NCT05240456: Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children

Not yet recruiting

1/2

Beta3-Agonists, Adrenergic, Standard behavioral Urotherapy, Anticholinergic drug, Solifenacin

Mansoura University

Voiding Disorders, Overactive Bladder

07/22

12/22

ChiCTR-TRC-13003148: Safety and efficacy of solifenacin succinate for treatment of catheter related bladder discomfort after endoscopic surgery in patients with upper urinary tract stone: a randomized, open ,controlled clinical study

Completed

126

no solifenacin after surgery ;given solifenacin after surgery

West China Hospital, Sichuan University; West China Hospital, Sichuan University, Own funds

catheter related bladder discomfort

NCT05767632: Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Completed

RoW

Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose), Vesicare & Betmiga, Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test), Mirfenacin MR, Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)

Genuine Research Center, Egypt, Hikma Pharma

Healthy

07/22

10/22

ChiCTR1800016280: Clinical trial of transcutaneous electrical nerve stimulation in treating refractory overactive bladder

Recruiting

N/A

oral solifenacin ;oral solifenacin and TENS

Chanjuan Zhang; Level of the institution：, Youth Scientific fund of Second Hospital of Shandong university

overactive bladder

ChiCTR1800019928: Clinical study for relieving symptoms of moderate and severe overactive bladder by electroacupuncture

Not yet recruiting

N/A

420

Electroacupuncture therapy was performed 3 times/week for the first 4 weeks and 2 times/week for the last 8 weeks, a total of 28 times ;Weak electroacupuncture stimulation was performed 3 times/week for the first 4 weeks and 2 times/week for the last 8 weeks, a total of 28 times ;Solifenacin succinate was given 5mg once a day for 32 weeks

West China Hospital, Sichuan University; West China Hospital, Sichuan University, National Key R&D Program of China（2017YFC1703602）

overactive bladder

NCT04437108: Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO

Completed

N/A

132

RoW

Li-SWT (suprapubic approach), Li-SWT (perineal approach), Li-SWT (combined approach), Sham treatment, Solifenacin

Mansoura University, Ahmed Mohamed Elshal

Overactive Bladder, Urinary Incontinence, Urge, Urgency-frequency Syndrome, Post Prostatectomy

04/22

07/22

NCT06184334: Management of OAB in Female Patients .

Completed

N/A

300

RoW

Solfenacin, Mirabegron, Tadalafil 5mg

Elsayed Abdelhalim Elsayed

Overactive Bladder

12/22

12/23

EASE-UMUI, NCT03787654: Electroacupuncture and Solifenacin for Urgency-predominant Mixed Urinary Incontinence

Recruiting

N/A

282

RoW

electroacupuncture, EA group, sham electroacupuncture, SEA group, Solifenacin, Drug group

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Mixed Urinary Incontinence, Urgency-predominant Mixed Urinary Incontinence

12/22

06/23

NCT04693897: Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Not yet recruiting

N/A

400

Mirabegron 50 MG, Solifenacin Succinate 5 MG

Chang Gung Memorial Hospital

Overactive Bladder Syndrome, Detrusor Overactivity

12/22

NCT05911594: IDB Injection Combined With PTNS for Managing Children With OAB Not Responding to Monotherapy

Completed

N/A

128

RoW

Solifenacin group, Percutaneous tibial nerve stimulation group, Intradetrusor BOTOX group, Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group

Benha University

BOTOX, Percutaneous Tibial Nerve Stimulation

02/23

NCT06024005: Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder

Completed

N/A

RoW

Oral Solifenacin 5mg, Kinzy 5mg, Transcutaneous Posterior Tibial Nerve Stimulation (TTNS), Urostim 2

Ege University

Overactive Bladder, Overactive Bladder Syndrome

05/23

NCT05709990: Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children

Completed

N/A

303

RoW

Solifenacin Succinate 5 MG Oral Tablet [Vesicare], standard urotherapy, Vitamin D3, Standard urotherapy

Xing Liu

Overactive Bladder

06/23

NCT06201013: Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children

Recruiting

N/A

150

RoW

urotherapy, Solifenacin Succinate, andard Urotherapy Combined with Solifenacin Drug Treatment, Vitamin D3, Standard Urotherapy Combined with Vitamin D supplementation

Xing Liu

Urinary Bladder, Overactive, Overactive Bladder, Urinary Incontinence, Urge

09/24

10/24

NCT05067478: Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Completed

N/A

403

Vibegron, GEMTESA

Urovant Sciences GmbH

Overactive Bladder

07/24

KALLIRROI, NCT06528613: Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.

Recruiting

N/A

450

Europe

Elpen Pharmaceutical Co. Inc.

Benign Prostatic Hyperplasia

09/25

DROP, NCT06110975: Deprescribing DRrugs for Overactive Bladder in General Practice

Recruiting

N/A

Europe

deprescribing-intervention, DROB (Deprescribing dRugs for Overactive Bladder)

Anne Estrup Olesen, University College of Northern Denmark

Overactive Bladder, Deprescribing, PIMS

12/25

12/26

NCT06489951: Efficacy and Safety of VDS+SU in the Treatment of OAB-dry in Children

Recruiting

N/A

180

RoW

Solifenacin, vitamin D, Standard behavioral therapy

Xing Liu, Beijing Children's Hospital, Shanghai Children's Hospital, Children's Hospital of Soochow University, Guizhou Provincial People's Hospital

Overactive Bladder, Pediatric Disorder

06/25

NCT05040984: Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Recruiting

N/A

500

RoW

Solifenacin Oral Tablet, Mirabegron 25mg

Far Eastern Memorial Hospital

Overactive Bladder Syndrome

12/24

NCT05798403: Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder

Recruiting

N/A

204

RoW

electroacupuncture, placebo medication, Solifenacin Succinate Tablets, Sham electroacupuncture

Shanghai University of Traditional Chinese Medicine, Longhua Hospital

Overactive Bladder

03/25

ACTRN12617000284369: Effectiveness of oral Solifenacin versus minimally invasive surgery in treatment of urge incontinence.

Recruiting

N/A

192

Mugla Sitki Kocman University, Ahmet Akin Sivaslioglu

Female urinary urge incontinence , Urinary stress incontinence , Solid fecal incontinence, Liquid fecal incontinence, Wind incontinence, Rectal prolapse

NCT05391425: The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function

Recruiting

N/A

150

RoW

no intervention

Istanbul University, Arnavutkoy State Hospital

Urge Incontinence, Urgency-frequency Syndrome

06/23

06/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Vesicare (solifenacin) / Astellas

ACTRN12611000796987: Effect of solifenacin and oxybutynin patch on cognitive function in elderly women with overactive bladder: An open-labelled, randomised, cross-over pilot study

Not yet recruiting

Bianca Wong, Department of Geriatric and Rehabilitation Medicine, Department of Obstetrics and Gynaecology, Memory Trials Centre

cognitive function, overactive bladder syndrome

ACTRN12610001022055: Solifenacin to relieve ureteral stent-related symptoms: A randomized, double-blinded placebo-controlled study

Recruiting

100

Mennonite Christian Hospital, Taiwan, Mennonite Christian Hospital, Taiwan

Ureteral stent-related symptoms after ureteroscopic stone manipulation.

ChiCTR-TNC-10000948: The Application of Overactive Bladder Symptom Score (OABSS) in Response to Treatment in Chinese Population

Completed

250

Vesicare 5mg-10mg/day Solifenacine

Beijing Hospital; Astellas Pharmaceuticals (China) Co., , Astellas Pharmaceuticals (China) Co.,

Overactive bladder

2006-001210-33: A cohort study of anticholinergic drugs in South Asian women with detrusor overactivity

Ongoing

Europe

Detrusitol XL, Vesicare, Detrusitol XL, Vesicare

University Hospitals of Leicester NHS Trust

ChiCTR-IPR-17011523: Effectiveness of solifenacin for managing of bladder spasms in patients with urethroplasty

Recruiting

315

solifenacin ;vitamin C

Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Self-Funding

bladder spasm

Not yet recruiting

RoW

solsolifenacin-sukcinát (solifenacini succinas), Tablet, Vesicare 5mg

Tesla Medical s.r.o., Tesla Medical s.r.o

Naive Subjects With Overactive Bladder (OAB), Female Subjects with hyperactive overactive bladder, Diseases [C] - Nervous System Diseases [C10]

Recruiting

Mirabegron 50mg ;Solifenacine ;Nil

Capital Medical University, Beijing Chaoyang Hospital; Capital Medical University, Beijing Chaoyang Hospital, Beijing Health system Special funds for High-level talents

Catheter Related Bladder Discomfort

NCT06197295: Efficacy of Combined Pharmacotherapy Versus Solifenacin with Vaginal Estrogen Cream for Women with Detrusor Overactivity

Recruiting

100

RoW

Solifenacin with vaginal estrogen cream, Premarin, Combination pharmacotherapy, Vesicare and Betmiga

Mackay Memorial Hospital

Urinary Bladder, Overactive, Effect of Drug

06/25

12/25

NCT06479720: Efficacy of Solifenacin or Mirabegron with Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

Recruiting

300

RoW

Mackay Memorial Hospital

Effect of Drug, Urinary Bladder, Overactive

12/24

06/25

NCT05494567: Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

Active, not recruiting

RoW

Tadalafil 5mg, rectalis 5 mg, Tamsulosin Hcl 0.4 mg, tamsulosin 0.4 mg, solifenacin 10 mg

Mansoura University

Benign Prostatic Hyperplasia, Overactive Bladder

08/22

NCT04909255: Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Recruiting

RoW

mirabegron, Betmiga, oxybutynin, tolterodine, solifenacin, Ditropan, tartrate, vesicare

China Medical University Hospital

Sjogren's Syndrome, Overactive Bladder Syndrome

08/22

SEPTOX, NCT04819360: Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

Terminated

Europe

VESIcare 10Mg Tablet, Vesicare, Botox 100 UNT Injection, Botox

Brigitte Schürch, Centre Hospitalier Universitaire Vaudois

Urinary Bladder, Neurogenic, Multiple Sclerosis

03/22

04/24

NCT06465576: Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

Recruiting

216

Europe

Solifenacin, Mirabegron, Solifenacin + Mirabegron

University of Aarhus

Urinary Incontinence in Children

12/27

NCT05968885: Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients with Detrusor Overactivity

Recruiting

300

RoW

Intradetrusor Botox® (onabotulinumtoxinA) injection, Combine Mirabegron and Solifenacin.

Mackay Memorial Hospital

Urinary Bladder, Overactive, Urodynamics, Effect of Drug

12/24

06/25

NCT04325880: Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Recruiting

240

RoW

Mirabegron 50 MG, Tamsulosin, Solifenacin Succinate 10 MG, Placebo oral tablet

Mansoura University

Ureteral Stent, Stent Related Symptoms

06/22

07/22

NCT05490082: Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Recruiting

100

RoW

Mirabegron, Propevirine, Solifenacin

Mansoura University

Voiding Disorders

03/23

10/23

BOSS PD, NCT03149809: Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

Completed

solifenacin, Vesicare, Pelvic floor muscle exercise-based behavioral therapy

VA Office of Research and Development

Overactive Bladder, Parkinson Disease

09/23

NCT05282069: A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Completed

607

RoW

DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg, Solifenacin 5mg, Solifenacin succinate placebo

Dong-A ST Co., Ltd.

Overactive Bladder

11/23

05/24

NCT06551246: Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children with Daytime Urinary Incontinence (BeDry)

Recruiting

236

Europe

Solifenacin, Mirabegron

University of Aarhus

Urinary Incontinence in Children

12/27

NCT04023253: Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

Recruiting

120

RoW

Mirabegron, Solifenacin

Far Eastern Memorial Hospital

Overactive Bladder Syndrome

12/24

NCT06803030: Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

Not yet recruiting

189

RoW

Tamsulosin Hydrochloride 0.4 mg, Cap. Urimax 0.4 mg, Solifenacin Succinate 5 mg, Tab. Solay 5 mg, Mirabegron 25 mg, Tab. Mirasin 25 mg

Bir Hospital, Nepal Health Research Council

Ureteral Stent-Related Symptom

06/25

12/26

NCT01530373: Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Recruiting

110

solifenacin, Vesicare, Clonidine, Catapres, Dixarit

University of Arkansas

Hot Flashes, Breast Cancer

07/26

09/27

MS.21.09.1680, NCT05240456: Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children

Not yet recruiting

1/2

Beta3-Agonists, Adrenergic, Standard behavioral Urotherapy, Anticholinergic drug, Solifenacin

Mansoura University

Voiding Disorders, Overactive Bladder

07/22

12/22

Completed

126

no solifenacin after surgery ;given solifenacin after surgery

West China Hospital, Sichuan University; West China Hospital, Sichuan University, Own funds

catheter related bladder discomfort

Completed

RoW

Genuine Research Center, Egypt, Hikma Pharma

Healthy

07/22

10/22

ChiCTR1800016280: Clinical trial of transcutaneous electrical nerve stimulation in treating refractory overactive bladder

Recruiting

N/A

oral solifenacin ;oral solifenacin and TENS

Chanjuan Zhang; Level of the institution：, Youth Scientific fund of Second Hospital of Shandong university

overactive bladder

ChiCTR1800019928: Clinical study for relieving symptoms of moderate and severe overactive bladder by electroacupuncture

Not yet recruiting

N/A

420

West China Hospital, Sichuan University; West China Hospital, Sichuan University, National Key R&D Program of China（2017YFC1703602）

overactive bladder

NCT04437108: Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO

Completed

N/A

132

RoW

Li-SWT (suprapubic approach), Li-SWT (perineal approach), Li-SWT (combined approach), Sham treatment, Solifenacin

Mansoura University, Ahmed Mohamed Elshal

Overactive Bladder, Urinary Incontinence, Urge, Urgency-frequency Syndrome, Post Prostatectomy

04/22

07/22

NCT06184334: Management of OAB in Female Patients .

Completed

N/A

300

RoW

Solfenacin, Mirabegron, Tadalafil 5mg

Elsayed Abdelhalim Elsayed

Overactive Bladder

12/22

12/23

EASE-UMUI, NCT03787654: Electroacupuncture and Solifenacin for Urgency-predominant Mixed Urinary Incontinence

Recruiting

N/A

282

RoW

electroacupuncture, EA group, sham electroacupuncture, SEA group, Solifenacin, Drug group

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Mixed Urinary Incontinence, Urgency-predominant Mixed Urinary Incontinence

12/22

06/23

NCT04693897: Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Not yet recruiting

N/A

400

Mirabegron 50 MG, Solifenacin Succinate 5 MG

Chang Gung Memorial Hospital

Overactive Bladder Syndrome, Detrusor Overactivity

12/22

NCT05911594: IDB Injection Combined With PTNS for Managing Children With OAB Not Responding to Monotherapy

Completed

N/A

128

RoW

Solifenacin group, Percutaneous tibial nerve stimulation group, Intradetrusor BOTOX group, Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group

Benha University

BOTOX, Percutaneous Tibial Nerve Stimulation

02/23

NCT06024005: Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder

Completed

N/A

RoW

Oral Solifenacin 5mg, Kinzy 5mg, Transcutaneous Posterior Tibial Nerve Stimulation (TTNS), Urostim 2

Ege University

Overactive Bladder, Overactive Bladder Syndrome

05/23

NCT05709990: Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children

Completed

N/A

303

RoW

Solifenacin Succinate 5 MG Oral Tablet [Vesicare], standard urotherapy, Vitamin D3, Standard urotherapy

Xing Liu

Overactive Bladder

06/23

NCT06201013: Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children

Recruiting

N/A

150

RoW

urotherapy, Solifenacin Succinate, andard Urotherapy Combined with Solifenacin Drug Treatment, Vitamin D3, Standard Urotherapy Combined with Vitamin D supplementation

Xing Liu

Urinary Bladder, Overactive, Overactive Bladder, Urinary Incontinence, Urge

09/24

10/24

NCT05067478: Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Completed

N/A

403

Vibegron, GEMTESA

Urovant Sciences GmbH

Overactive Bladder

07/24

KALLIRROI, NCT06528613: Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.

Recruiting

N/A

450

Europe

Elpen Pharmaceutical Co. Inc.

Benign Prostatic Hyperplasia

09/25

DROP, NCT06110975: Deprescribing DRrugs for Overactive Bladder in General Practice

Recruiting

N/A

Europe

deprescribing-intervention, DROB (Deprescribing dRugs for Overactive Bladder)

Anne Estrup Olesen, University College of Northern Denmark

Overactive Bladder, Deprescribing, PIMS

12/25

12/26

NCT06489951: Efficacy and Safety of VDS+SU in the Treatment of OAB-dry in Children

Recruiting

N/A

180

RoW

Solifenacin, vitamin D, Standard behavioral therapy

Xing Liu, Beijing Children's Hospital, Shanghai Children's Hospital, Children's Hospital of Soochow University, Guizhou Provincial People's Hospital

Overactive Bladder, Pediatric Disorder

06/25

NCT05040984: Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Recruiting

N/A

500

RoW

Solifenacin Oral Tablet, Mirabegron 25mg

Far Eastern Memorial Hospital

Overactive Bladder Syndrome

12/24

NCT05798403: Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder

Recruiting

N/A

204

RoW

electroacupuncture, placebo medication, Solifenacin Succinate Tablets, Sham electroacupuncture

Shanghai University of Traditional Chinese Medicine, Longhua Hospital

Overactive Bladder

03/25

ACTRN12617000284369: Effectiveness of oral Solifenacin versus minimally invasive surgery in treatment of urge incontinence.

Recruiting

N/A

192

Mugla Sitki Kocman University, Ahmet Akin Sivaslioglu

Female urinary urge incontinence , Urinary stress incontinence , Solid fecal incontinence, Liquid fecal incontinence, Wind incontinence, Rectal prolapse

NCT05391425: The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function

Recruiting

N/A

150

RoW

no intervention

Istanbul University, Arnavutkoy State Hospital

Urge Incontinence, Urgency-frequency Syndrome

06/23

06/24

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites